No Data
Aodong, Jilin: 2024 Annual Report
Aodong, Jilin: 2024 Annual Report Summary
Brokerage morning meeting highlights: Countermeasures against tariffs boost Shenzhen Agricultural Products Group prices, the planting chain directly benefits.
At today's Brokerage morning meeting, CITIC SEC believes that countermeasures against tariffs boost the prices of Shenzhen Agricultural Products Group, which directly benefits the planting chain; HAITONG SEC proposed a bullish view on the relative yields of the Banks Sector in April; Galaxy Securities stated that it focuses on Gold and countermeasures against rare earths.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Jilin Aodong Pharmaceutical Group (000623.SZ): Yanji Pharmaceutical has obtained the pharmaceutical registration certificate for polyethylene glycol eye drops.
On March 21, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) recently announced that its holding subsidiary, Jilin Aodong Pharmaceutical Group Yanji Co., Ltd. (referred to as "Yanji Pharmaceutical"), received the "Pharmaceutical Registration Certificate" issued by the National Medical Products Administration for the specification of Polyvinyl Alcohol Eye Drops: 1.4% (0.4ml: 5.6mg). The indications for Polyvinyl Alcohol Eye Drops include serving as a lubricant to prevent or treat symptoms of eye dryness, foreign body sensation, eye fatigue, and to improve dry eye symptoms.
Jilin Aodong Pharmaceutical Group (000623.SZ): Actively exploring the possibilities of optimizing drug screening, clinical trial design, and other aspects through AI technology.
On March 19, Gelonghui reported that Jilin Aodong Pharmaceutical Group (000623.SZ) stated on the investor interaction platform that the company always pays close attention to the technological changes and market trends in the Medical health industry, and maintains a high level of interest in the application prospects of AI technology in pharmaceutical research and development, production management, and the health sector. Currently, the company has introduced information technology, digitalization, and intelligent technology in the entire pharmaceutical process management, achieving equipment interconnectivity, data sharing, and flexible manufacturing through smart factory construction, laying a foundation for further exploration of AI empowerment in the future. On the research and development side, the company continues to conduct research on classic formulas of Traditional Chinese Medicine, formula granules, and Innovative Drugs, and actively explores.
